Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

SkinBioTherapeutics plc (LSE:SBTX): What the AIM and London Market Is Watching Next

SkinBioTherapeutics plc (LSE:SBTX) is drawing attention within the AIM market as investors weigh its latest company-specific developments against the wider outlook for skin health science, microbiome research and topical products. The central question on 13 October 2026 is whether the current investment narrative can …

Ankur Sharma | 13 October 2026

What EDX Medical's (LSE:EDX) Move From Aquis Means for Its Debut on the FTSE AIM All Share Index

EDX Medical develops and distributes diagnostic tests and related services. Its activities include the distribution of prostate cancer tests, a range of tests awaiting regulatory approval and more complex diagnostic products. The company was originally listed on the Aquis Growth Market in 2021, renamed …

Ankur Sharma | 13 October 2026

Why EKF Diagnostics (LSE:EKF) is leaning on margins as a FTSE AIM All Share Index constituent

EKF is a diagnostics business that makes point-of-care analysers and consumables, notably for haematology testing such as haemoglobin measurement, alongside a life sciences operation that provides contract manufacturing and fermentation services. It also produces beta-hydroxybutyrate (β-HB) reagents used in ketone testing. The life sciences …

Ankur Sharma | 13 October 2026

What Fusion Antibodies (LSE:FAB) Is Counting On From OptiMAL in the FTSE AIM All Share Index

Fusion was spun out of Queen's University Belfast in 2001. It provides antibody discovery, engineering, production and optimisation services to pharmaceutical and biotechnology customers developing therapeutic and diagnostic products. Its OptiMAL technology is a platform designed to support antibody discovery and was commercially launched …

Ankur Sharma | 13 October 2026

How Faron Pharmaceuticals is preparing its next bexmarilimab trial as a FTSE AIM All Share Index biotech (LSE:FARN)

Headquartered in Turku, Faron is a clinical-stage biopharmaceutical company listed on AIM and on Nasdaq First North Finland. Its approach targets Clever-1, a receptor on immune cells called macrophages, with the aim of reprogramming these myeloid cells to switch on the body's anti-tumour immunity. …

Ankur Sharma | 13 October 2026

What Feedback plc (LSE:FDBK) Is Waiting For From the NHS as a Constituent of the FTSE AIM All Share Index

Feedback describes itself as a clinical infrastructure specialist. Its main product, Bleepa, is a platform that allows clinicians and care teams to work asynchronously on patient pathways, with the aim of reducing unnecessary outpatient appointments and speeding up decisions. The software is sold on …

Ankur Sharma | 13 October 2026

What Eco Animal Health's (LSE:EAH) first vaccine launch means for its FTSE AIM All Share Index story

ECO Animal Health develops and sells animal health products, with a long-established franchise in Aivlosin, an antibiotic used in pigs and poultry. It sells through a global network, with major markets in North America, Latin America, China and Japan, and South and Southeast Asia. …

Ankur Sharma | 13 October 2026

Oxford BioMedica plc (LSE:OXB): What Is Driving Investor Attention in the UK Market on 13 October 2026?

The investment discussion centres on viral-vector development and manufacturing, with attention on CDMO contract wins, capacity use and cash conversion.

Ankur Sharma | 13 October 2026

What Renalytix's (LSE:RENX) £10m Fundraise Means for Its Place on the FTSE AIM All Share Index

Renalytix is an artificial intelligence-enabled diagnostics business focused on chronic kidney disease. Its kidneyintelX.dkd test is an FDA-approved, Medicare-reimbursed prognostic test designed to assess early-stage risk in diabetic kidney disease. The shares trade on AIM and on the US OTCQB market. Medicare reimbursement is …

Divya Sood | 13 October 2026

Smith & Nephew plc (LSE:SN.): What could move this FTSE 100 stock next as investors reassess its growth outlook?

Smith & Nephew plc (LSE:SN.) is in focus on 13 October 2026 because investors are weighing company-specific developments alongside the wider direction of UK equities. The central question is whether its operating performance can translate into durable earnings, cash flow and shareholder value. For …

Ankur Sharma | 13 October 2026
Support

Hi! How can we help you today?

Loading…